Compare OIS & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OIS | TRDA |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 682.7M | 481.6M |
| IPO Year | 2000 | 2021 |
| Metric | OIS | TRDA |
|---|---|---|
| Price | $11.16 | $14.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $14.00 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 782.9K | 162.5K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,088,133,000.00 | $25,421,000.00 |
| Revenue This Year | $3.73 | $39.97 |
| Revenue Next Year | $5.36 | $50.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 62.26 | N/A |
| 52 Week Low | $3.33 | $4.93 |
| 52 Week High | $14.50 | $14.36 |
| Indicator | OIS | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 61.47 |
| Support Level | $5.72 | $10.84 |
| Resistance Level | $12.79 | N/A |
| Average True Range (ATR) | 0.49 | 0.75 |
| MACD | -0.09 | 0.12 |
| Stochastic Oscillator | 21.04 | 87.79 |
Oil States International Inc is a provider of manufactured products and services to customers in the energy, military and industrial sectors. The company operates through three business segments - Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. Its customers include many national oil and natural gas companies, and independent oil and natural gas companies, offshore drilling companies and other oilfield service, defense and industrial companies.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.